
    
      This is an open label, single-arm, multicenter Phase I/II study of IBI377 in combination with
      corticosteroids as first-line treatment of subjects with Grade II to IV aGVHD. In Phase I,
      the PK, safety, tolerability and efficacy of IBI377 will be assessed in 12 subjects. In Phase
      II, the efficacy and safety will be assessed in 48 subjects.
    
  